tbuckley/cabot-search huggingface dataset:
Abstract P005: Improving Heart Health in the Workplace: Results From the First Year of the American Heart Association’s Workplace Health Achievement Index
Authors: Chris Calitz, Kristin Pham, Adela Santana, Eduardo Sanchez, Ross Arena, Gregg C Fonarow
Journal: Circulation (2017)

Background: Comprehensive workplace wellness programs (CWWPs) have the potential to improve the heart health of the US workforce. To accelerate the adoption of these programs, the American Heart Association launched the Workplace Health Achievement Index (WHAI). The WHAI is an online scorecard that evaluates a workplace’s culture of health and the aggregate heart health score of its workforce as measured by Life’s Simple 7. Evidence from other workplace scorecards indicate that smaller companies achieve lower scores. Objective: To quantify differences in WHAI scores and score components between smaller (&lt;250 employees) and larger (250+ employees) worksites. Methods: The total WHAI score is derived from 55 structure and process measures across seven best-practice domains and performance metrics based on employee Life’s Simple 7 data. Data from the first WHAI cycle (Feb 1 - June 30, 2016) were analyzed from 239 worksites that provided structure and process information. All data were stratified according to company size (smaller vs. larger). Differences in practice and performance measures were assessed across groups using Pearson chi-square tests or paired t-tests. Results: Overall, 5% of workplaces submitted the required amount of heart health metrics data (≥25% of employees) for eligibility. Smaller companies achieved a lower total WHAI score and lower scores across all domains except for Partnerships (Table 1). Conclusion: Lower WHAI scores for smaller companies may be due to limited resources and capacity to implement CWWPs. Low submission of performance metrics highlights the challenge of including these data in a comprehensive assessment of CWWPs. To meet its 2020 Goals, AHA should consider providing smaller companies with resources to implement CWWPs and develop strategies to increase submission of employee Life’s Simple 7 data. Table 1: Differences in mean AHA Index scores between small and large companies *Sample sizes too small for meaningful comparison.
Abstract 18897: Genetically Purified Induced Pluripotent Stem Cell (IPSC)-derived Cardiomyocytes Engraft and Improve Remodeling and Ventricular Function After Myocardial Infarction in Mice
Authors: Andreas Martens, Sebastian V Rojas, George Kensah, Alexander Rotaermel, Hassina Baraki, Axel Haverich, Ulrich Martin, Ina Gruh, Ingo Kutschka
Journal: Circulation (2012)

Induced pluripotent stem cells (iPSC) can be differentiated into cardiomyocytes in vitro and represent a possible autologous cell source for myocardial repair. The aim of this study was to determine the engraftment and functional effects of murine iPSC-derived cardiomyocytes (iPSC-CMs) in a mouse model of myocardial infarction. A genetic purification protocol was used to maximize CM yield and purity. Methods: Murine iPSCs were genetically modified to express a Zeocin resistance gene under control of the cardiac-specific α-myosin heavy chain (α-MHC) promoter. Differentiation was initiated by hanging drop technique. Embryoid bodies were brought into suspension culture. CM selection was started on d7 (400 µg/ml Zeocin). 1x10^6 cell tracer (CFDA-SE) marked iPSC-CMs were transplanted into the hearts of LAD-ligated mice. Animals were treated with placebo (PBS, n = 14) or iPSC-CMs (n = 35). Heart function was evaluated by magnetic resonance imaging (MRI) and conductance catheter (CC) analysis. In vitro and in vivo differentiation was investigated. Follow up after iPSC-CM transplantation was 1 and 2.5 weeks (histological assessment only) or 4 weeks (including functional analysis). Results: iPSC-CM purity was &gt;90% after antibiotic resistance selection. Intramyocardial transplantation of iPSC-CMs significantly improved myocardial remodeling (e.g. infarct size and ventricular wall thickness, P&lt;0.01) and left ventricular function 4 weeks after LAD-ligation (e.g. LV-EF, P&lt;0.01). iPSC-CMs engrafted within ischemic myocardium, expressed cardiac markers and exhibited sarcomeric structures up to 2.5 weeks after transplantation. Connexin staining did not show functional coupling with host myocardium. Conclusions: iPSCs can effectively be differentiated into cardiomyocytes with high purity by genetic engineering techniques. iPSC derived cardiomyocytes engraft within the myocardium of LAD-ligated mice and improve left ventricular function. Future research has to focus on long term survival and functional coupling to host myocardium.
Abstract 16029: Lifestyle Modifications Regress Coronary Artery Atherosclerosis
Authors: Sunny Jhamnani, Dhavalkumar Patel, Fred King, Layla Heimlich, Joseph Lindsay
Journal: Circulation (2012)

Background and Purpose: Coronary artery plaque progression has been associated with significant cardiovascular morbidity and mortality. Even though, lifestyle modifications are the cornerstone of t...
Stem cell transplantation
Authors: Nicolaas Schaap
Journal: HemaSphere (2019)

Learning goals Preparedness for possible nuclear terrorism is important and possible, multiple parts for preparedness are in place. The current state of acute radiation syndrome (ARS) does not substantially differ from the management of pancytopenia in other settings, such as after treatment with myelosuppressive chemotherapy. HSCT patients have a high likelihood of severe dysbiosis early after transplantation which is mediated by broad spectrum antibiotics and GvHD itself while real decontamination is rarely achieved. Microbiota modulation offers a new option for treatment or even prophylaxis of GvHD. The number of patients transplanted using Haplo-HSCT is increasing consistently in Europe and United States. Haplo-HSCT with the use of PTCy for GVHD prophylaxis, allows low incidence of grade III to IV acute GVHD, chronic GVHD, and comparable survival with HLA-matched unrelated and cord blood transplantation. Introduction Worldwide radiation accidents are rare, however we learned from the past that these events ask for serious planning in the health care system.. Nuclear accidents in the Chernobyl (1986) and Fukushima (2011) power plants demonstrated that we should draw the attention of the real risk of radiation accidents to the health care. In his presentation Dr Chao will elaborate on the acute radiation syndrome (ARS) in humans. Efficient triage to identify victims without a lethal dose of irradiation who can be rescued is obligatory. On the other hand, the current management of ARS does not differ a lot from the management of pancytopenia in other settings. Extensive triage algorithms and appropriate standardized operation procedures are currently available to improve survival in these victims. Prof E Holler will focus in his lecture on new insights concerning the changes in the microbiome by using antibiotic prophylaxis that are regularly applied in SCT to prevent infectious complications and GVHD. In contrast, using these antibiotics we induce a massive loss of diversity (dysbiosis) which was associated with an increased risk of GVHD and late transplant related mortality. New molecular sequencing techniques demonstrate not only the loss but also the skewing of the microbiome towards an abundance of single pathogenic bacteria, especially anaerobic species. Fecal microbiota transfer (FMT) may play an important role to restore the diversity of the microbiome. The recent introduction of new conditioning regimens and graft manipulation techniques have boosted the implementation of haplo-identical stem cell transplantation and offers better chances of survival in this patient category. Dr Ruggeri will talk in her presentation about the two most frequent used conditioning regimens that changed the world of haplo-identical stem cell transplantation, based either on the use of post-transplant cyclophosphamide (PTCy) or on anti-thymocyte globulin (ATG). She will also discuss different stem cell sources (bone marrow vs PBSC), the intensity of the conditioning regimens (RIC vs MAC), new complications and challenges we have to deal with.
Effects of Calcium, Magnesium, and Potassium Concentrations on Ventricular Repolarization in Unselected Individuals
Authors: Raymond Noordam, William J. Young, Reem Salman, Jørgen K. Kanters, Marten E. van den Berg, Diana van Heemst, Henry J. Lin, Sandhi Maria Barreto, Mary L. Biggs, Ginevra Biino, Eulalia Catamo, Maria Pina Concas, Jun Ding, Daniel S. Evans, Luisa Foco, Niels Grarup, Leo-Pekka Lyytikäinen, Massimo Mangino, Hao Mei, Peter J. van der Most, Martina Müller-Nurasyid, Christopher P. Nelson, Yong Qian, Linda Repetto, M. Abdullah Said, Nabi Shah, Katharina Schramm, Pedro G. Vidigal, Stefan Weiss, Jie Yao, Nuno R. Zilhao, Jennifer A. Brody, Peter S. Braund, Marco Brumat, Eric Campana, Paraskevi Christofidou, Mark J. Caulfield, Alessandro De Grandi, Anna F. Dominiczak, Alex S.F. Doney, Gudny Eiriksdottir, Christina Ellervik, Luana Giatti, Martin Gögele, Claus Graff, Xiuqing Guo, Pim van der Harst, Peter K. Joshi, Mika Kähönen, Bryan Kestenbaum, Maria F. Lima-Costa, Allan Linneberg, Arie C. Maan, Thomas Meitinger, Sandosh Padmanabhan, Cristian Pattaro, Annette Peters, Astrid Petersmann, Peter Sever, Mortiz F. Sinner, Xia Shen, Alice Stanton, Konstantin Strauch, Elsayed Z. Soliman, Kirill V. Tarasov, Kent D. Taylor, Chris H.L. Thio, André G. Uitterlinden, Simona Vaccargiu, Melanie Waldenberger, Antonietta Robino, Adolfo Correa, Francesco Cucca, Steven R. Cummings, Marcus Dörr, Giorgia Girotto, Vilmundur Gudnason, Torben Hansen, Susan R. Heckbert, Christian R. Juhl, Stefan Kääb, Terho Lehtimäki, Yongmei Liu, Paulo A. Lotufo, Colin N.A. Palmer, Mario Pirastu, Peter P. Pramstaller, Antonio Luiz P. Ribeiro, Jerome I. Rotter, Nilesh J. Samani, Harold Snieder, Tim D. Spector, Bruno H. Stricker, Niek Verweij, James F. Wilson, James G. Wilson, J. Wouter Jukema, Andrew Tinker, Christopher H. Newton-Cheh, Nona Sotoodehnia, Dennis O. Mook-Kanamori, Patricia B. Munroe, Helen R. Warren
Journal: Journal of the American College of Cardiology (2019)
Three- versus six-month adjuvant FOLFOX or CAPOX for high-risk stage II and stage III colon cancer patients: the efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) project
Authors: J. Souglakos, I. Boukovinas, S. Kakolyris, S. Xynogalos, N. Ziras, A. Athanasiadis, N. Androulakis, A. Christopoulou, M. Vaslamatzis, A. Ardavanis, C. Emmanouilides, I. Bompolaki, C. Kourousis, P. Makrantonakis, C. Christofyllakis, E. Athanasiadis, N. Kentepozidis, A. Karampeazis, U. Katopodi, A. Anagnosopoulos, G. Papadopoulos, E. Prinarakis, A. Kalisperi, D. Mavroudis, V. Georgoulias
Journal: Annals of Oncology (2019)
Association Between Inpatient Echocardiography Use and Outcomes in Adult Patients With Acute Myocardial Infarction
Authors: Quinn R. Pack, Aruna Priya, Tara Lagu, Penelope S. Pekow, Joshua P. Schilling, William L. Hiser, Peter K. Lindenauer
Journal: JAMA Internal Medicine (2019)

Guidelines recommend that patients with acute myocardial infarction (AMI) undergo echocardiography for assessment of cardiac structure and ejection fraction, but little is known about the association between echocardiography as used in routine clinical management of AMI and patient outcomes.To examine the association between risk-standardized hospital rates of transthoracic echocardiography and outcomes.This retrospective cohort study of data from 397 US hospitals that contributed to the Premier Healthcare Informatics inpatient database from January 1, 2014, to December 31, 2014, used International Classification of Diseases, Ninth Revision (ICD-9) codes to identify 98 999 hospital admissions for patients with AMI. Data were analyzed between October 2017 and January 2019.Rates of transthoracic echocardiography.Inpatient mortality, length of stay, total inpatient costs, and 3-month readmission rate.Among the 397 hospitals with more than 25 admissions for AMI in 2014, a total of 98 999 hospital admissions for AMI were identified for analysis (38.2% women; mean [SD] age, 66.5 [13.6] years), of which 69 652 (70.4%) had at least 1 transthoracic echocardiogram performed. The median (IQR) hospital risk-standardized rate of echocardiography was 72.5% (62.6%-79.1%). In models that adjusted for hospital and patient characteristics, no difference was found in inpatient mortality (odds ratio [OR], 1.02; 95% CI, 0.88-1.19) or 3-month readmission (OR, 1.01; 95% CI, 0.93-1.10) between the highest and lowest quartiles of echocardiography use (median risk-standardized echocardiography use rates of 83% vs 54%, respectively). However, hospitals with the highest rates of echocardiography had modestly longer mean lengths of stay (0.23 days; 95% CI, 0.04-0.41; P = .01) and higher mean costs ($3164; 95% CI, $1843-$4485; P < .001) per admission compared with hospitals in the lowest quartile of use. Multiple sensitivity analyses yielded similar results.In patients with AMI, hospitals in the quartile with the highest rates of echocardiography showed greater hospital costs and length of stay but few differences in clinical outcomes compared with hospitals in the quartile with the lowest rates of echocardiography. These findings suggest that more selective use of echocardiography might be used without adversely affecting clinical outcomes, particularly in hospitals with high rates of echocardiography use.
AB0524 SERUM BAFF AND APRIL AS CANDIDATE BIOMARKERS IN SYSTEMİC LUPUS ERYTHEMATOSUS (SLE): A PROSPECTIVE FOLLOW-UP STUDY
Authors: Selma Sarı, Suzan Çınar, Bahar Artim-Esen, Ahmet Gul, Mahdume Lale Ocal, Gunnur Deniz, Murat Inanc
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background:</h3> BAFF and APRIL are cytokines involved in B cell development and they take place in the pathogenesis of SLE. <h3>Objectives:</h3> The aim of this study was to investigate the relationship between serum BAFF/APRIL levels with clinical features and disease activity in SLE patients. <h3>Methods:</h3> We included 79 patients with SLE (ACR criteria) and 27 healthy controls into the study. Serum BAFF and APRIL levels were assessed by ELISA. In 19 patients with active disease at the time of the assessment BAFF/APRIL levels were reassessed at least 6 months later (mean 7.8 months) and disease activity was evaluated by SLEDAI. New renal involvement was observed in 16 patients during the study and renal involvement was previously detected in 12 patients. <h3>Results:</h3> Although both BAFF (median 0.7 vs 0.41 ng/ml) and APRIL (median 2.3 vs 1.05 ng/ml)levels were higher in patients with SLE compared to the control group (p &lt;0.001), no correlation was found between BAFF/APRIL levels and SLEDAI scores. Only 9 patients (11.4%) had both BAFF and APRIL in normal range (95% confidence interval). When patients were grouped according to disease activity as no activity (SLEDAI = 0), low disease activity and active disease, there was no difference in BAFF/APRIL levels between groups. Serum BAFF levels were higher in patients with renal disease activity (median 0.94 ng/ml vs 0.61 ng/ml, p=0,01), and there was a positive correlation between APRIL levels and proteinuria (r=0.42, p=0,02). There was no association between BAFF/APRIL levels and anti-dsDNA positivity but a weak inverse correlation was observed between BAFF and C3 levels (r=0.25, P=0.02). No correlation was found between BAFF/APRIL levels and renal SLEDAI score, renal histopathology activity and chronicity index scores. In the active disease group after follow-up, there was no significant change in BAFF (from 1,63 ng/ml to 1,2 ng/ml) and APRIL levels (from 2,11 ng/ml to 2,31 ng/ml). <h3>Conclusion:</h3> BAFF/APRIL levels were found to be significantly higher in patients with SLE compared to controls, but no association with disease activity was found. BAFF levels are correlated with decreased C3 levels. These results suggest that both cytokines are involved in the pathogenesis of SLE, and that serum BAFF and APRIL levels can be valuable as a biomarker in SLE especially in patients with renal activity. Long-term studies on the effect of treatment are needed. <h3>Disclosure of Interests:</h3> None declared
FRI0488 ROLE OF DUAL-PHOTON X-RAY ABSORPTIOMETRY (DXA) IN PREDICTION OF REFRACTURE AND MORTALITY
Authors: Sara Ganhão, Miguel Guerra, Francisca Aguiar, Raquel Ferreira, Teresa Martins-Rocha, Ana Filipa Águeda, Georgina Terroso, Eva Mariz, Carlos Vaz, Lúcia Costa
Journal: Annals of the Rheumatic Diseases (2019)

<h3>Background</h3> The presence of a fragility fracture leads to a high risk for a subsequent fracture and mortality. Although bone mineral density (BMD) does not reflect the real fracture risk in many conditions, it is a well-established predictor of fracture risk and for many years, dual-photon X-ray absorptiometry (DXA) has been the reference standard for measuring BMD. <h3>Objectives</h3> To evaluate the predictive significance of femur BMD and T-score obtained by DXA in the outcomes refracture and mortality of elderly patients with a previous fragility hip fracture. <h3>Methods</h3> Longitudinal retrospective study of patients referred to the Rheumatology department's Fracture Liaison Service (FLS) from march 2015 until march 2017 aged ≥65 years old. Demographic and clinical data were collected including DXA results. Statistical analysis was performed with STATA. Hazard ratios (HR) were calculated through cox regression, adjusted to age and degree of dependence. <h3>Results</h3> From a total of 522 patients, 214 performed DXA (77.6% female; median (min-max) age 82 (65-99) years; 65.4% autonomous). Twenty seven patients died (median days until death=457, min 160, max 1049) and 18 had a subsequent fracture (median days until refracture 343.5, min 160, max 1049); 129 patients maintained follow-up. Mean serum total femur BMD, g/cm<sup>2</sup> (SD) was 0.7 (0.14) and mean total femur T-score (SD) was -2.6, (1.1). 127 (59.3%) patients had T-score ≤-2.5. After multivariable analysis, higher femur BMD and T-score were predictors of better survival outcome (HR 0.01, <i>p</i>=0.023; HR 0.67, p=0.038, respectively). Nevertheless, none of them predicted refracture outcome. (HR: 0.08; 95%CI [0.01-5.16]; <i>p</i>=0.240); HR: 0.81; 95%CI [0.51-1.28]; <i>p</i><i>=</i>0.361). <h3>Conclusion</h3> DXA is important in the management of patients with bone fragility syndromes. Our sample suggests that femur BMD/T-score had significant impact on survival outcome. Thus it can be a predictor of mortality with relevant role in daily practice. <h3>References</h3> [1] Browner WS, Seeley DG, Vogt TM, Cummings SR. Non-trauma mortality in elderly women with low bone mineral density. Study of Osteoporotic Fractures Research Group. Lancet1991;338:355–8. [2] Trivedi DP, Khaw KT. Bone mineral density at the hip predicts mortality in elderly men. Osteoporos Int2001;12:259–65. [3] Cortet B. Does low bone mineral density predict mortality?Joint Bone Spine. 2016Dec;83(6):623-624 [4] Roux C1, Briot K2. Current role for bone absorptiometry. Joint Bone Spine. 2017Jan;84(1):35-37. [5] Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K,et al. Bone density at various sites for prediction of hip fractures. The Study of Osteoporotic Fractures Research Group. Lancet. 1993;341:72–75. <h3>Disclosure of Interests</h3> None declared
Abstract 16019: What Does Carotid Intima-Media Thickness and Plaque Add to Prediction of Stroke and Cardiovascular Disease Risk in Older Adults? The Cardiovascular Health Study
Authors: Julius M Gardin, Traci M Bartz, Joseph F Polak, Daniel O'Leary, Nathan D Wong, John S Gottdiener
Journal: Circulation (2012)

Background: Framingham Risk Score (FRS) and other traditional stroke and cardiovascular disease (CVD) risk factors are limited since the majority of incident stroke and CVD events occur in low- and...
A renal risk score for ANCA-associated glomerulonephritis
Authors: Maria A.C. Wester Trejo, Emma E. van Daalen, Annelies E. Berden, Ron Wolterbeek, Leendert A. van Es, Willem J.W. Bos, Franco Ferrario, E. Christiaan Hagen, J. Charles Jennette, Kensuke Joh, Irmgard Neumann, Laure-Hélène Noël, Charles D. Pusey, Jan A. Bruijn, Ingeborg M. Bajema
Journal: Kidney International (2019)
Cannabis Use in Pregnancy
Authors: Michael Silverstein, Elizabeth A. Howell, Barry Zuckerman
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal